5-(3-chloropropyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one | 1380392-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 5-(3-chloropropyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one
• 英文别名: 5-(3-chloropropyl)pyrrolo[1,2-a]quinoxalin-4-one
• CAS: 1380392-06-2
• 化学式: C₁₄H₁₃ClN₂O
• 分子量: 260.723
• InChiKey: WXPLBOXMTJILCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  25.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(4-氯苯基)哌啶 、 5-(3-chloropropyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 化合物JMS-17-2
  参考文献：
  名称：

  Methods of Inhibiting Metastasis from Cancer

  摘要：

  本发明涉及一种用于预防或治疗被诊断为癌症的患者中的转移的组合物。本发明还包括一种用于预防或治疗被诊断为癌症的患者中的转移的方法，其中该方法包括向需要该药物的患者投与至少一种药用制剂，该制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。

  公开号：

  US20120141471A1
• 作为产物：
  描述：

  1-溴-3-氯丙烷 、 吡咯并[1,2-a]喹喔啉-4(5H)-酮 在 NaH 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-(3-chloropropyl)pyrrolo[1,2-a]quinoxalin-4(5H)-one
  参考文献：
  名称：

  Methods of Inhibiting Metastasis from Cancer

  摘要：

  本发明涉及一种用于预防或治疗被诊断为癌症的患者中的转移的组合物。本发明还包括一种用于预防或治疗被诊断为癌症的患者中的转移的方法，其中该方法包括向需要该药物的患者投与至少一种药用制剂，该制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。

  公开号：

  US20120141471A1

文献信息

• Compounds useful for inhibiting metastasis from cancer and methods using same
  申请人：Fatatis Alessandro

  公开号：US09375474B2

  公开（公告）日：2016-06-28

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.

  本发明包括用于预防或治疗诊断出患有癌症的受试者的转移的组合物。本发明还包括用于预防或治疗诊断出患有癌症的受试者的转移的方法，其中该方法包括向需要该药物的受试者施用包含至少一种药学上可接受的载体和至少一种CX3CR1或Fractalkine拮抗剂的药物制剂的有效量。
• Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same
  申请人：Drexel University College of Medicine Philadelphia Health & Education Corporation d/b/a

  公开号：US20130156761A1

  公开（公告）日：2013-06-20

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX 3 CR1 or fractalkine antagonist.

  本发明涉及一种对已被诊断患有癌症的受试者预防或治疗转移的有用组合物。本发明还涉及一种预防或治疗已被诊断患有癌症的受试者的转移的方法，其中该方法包括向需要该药物的受试者施用至少一种药物制剂，该药物制剂包括至少一种药用载体和至少一种CX3CR1或fractalkine拮抗剂的有效量。
• Methods of inhibiting metastasis from cancer
  申请人：Fatatis Alessandro

  公开号：US08435993B2

  公开（公告）日：2013-05-07

  The present invention includes compositions that are useful in preventing or treating metastasis in a subject diagnosed with cancer. The present invention also includes methods of preventing or treating metastasis in a subject diagnosed with cancer, wherein the method comprises administering to the subject in need thereof an effective amount of a pharmaceutical formulation comprising at least one pharmaceutically acceptable carrier and at least one CX3CR1 or fractalkine antagonist.

  本发明涉及一种用于预防或治疗已被诊断为癌症的受试者中转移的组合物。本发明还包括用于预防或治疗已被诊断为癌症的受试者中转移的方法，其中该方法包括向需要该药物的受试者施用包含至少一种药用载体和至少一种CX3CR1或Fractalkine拮抗剂的制药配方的有效剂量。
• METHODS OF INHIBITING METASTASIS FROM CANCER
  申请人：Philadelphia Health and Education Corporation D/B/A

  公开号：EP2648754A2

  公开（公告）日：2013-10-16
• CX3CR1 Small Molecule Antagonists, and Methods Using Same
  申请人：SALVINO Joseph M.

  公开号：US20200062768A1

  公开（公告）日：2020-02-27

  The invention provides compounds that are fractalkine receptor agonists and useful in treating, preventing or minimizing metastasis in a subject diagnosed with cancer. The compounds of the invention are further useful in treating central nervous system diseases (such as, but not limited to, HIV Associated Neurocognitive Disorders (HAND), and/or Alzheimer's disease), pain, inflammation (such as, but not limited to, arthritis), cardiovascular disease (such as, but not limited to, undesired vascular smooth muscle proliferation, atherosclerosis, coronary vascular endothelial dysfunction, and/or coronary artery disease), and/or multiple sclerosis.